Disc Medicine Reports Third-Quarter 2026 Results and Business Update
Disc Medicine said its pivotal Phase 3 APOLLO trial of bitopertin in erythropoietic protoporphyria successfully met a
Story updates
01:33:48 PM UTC
SquawkNews
Disc Medicine reported a third-quarter 2026 net loss of $59.5 million, compared with $62.3 million in the prior-year quarter. Cash, cash equivalents and marketable securities totaled $682.8 million at September 30, and an October public offering added approximately $485.9 million in net proceeds. T…
01:37:38 PM UTC
SquawkNews
Disc Medicine reported an APOLLO pivotal trial readout indicating potential clinical benefit for bitopertin in EPP. The company also reported initial RESTORE-PV data and an anticipated end-of-Phase 2 FDA meeting for selcodebart in the fourth quarter.Material DetailsContext by AI AnalystThe APOLLO r…